Protocol Ledger

NCT06414954 · Phase II · RECRUITING

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Interventional Phase II clinical trial protocol NCT06414954 sponsored by NMD Pharma in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-16 Enrollment: 84 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06414954
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)84 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06414954
Protocol FieldVerified Registry Value
NCT IdentifierNCT06414954
Consolidated Lead SponsorNMD Pharma
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment84 participants (ESTIMATED)
Registered Start Date2024-05-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI